Hepatitis/MASH

HCV rates 3 times higher in patients with lupus.

The FDA has accepted AbbVie’s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P).

Top articles of the week from Specialty Pharmacy Times.

Fake hepatitis C pills are entering the distribution network through back-channel wholesalers.

RG-101 placed on clinical hold last year after a second reported case of jaundice.

Regulus Therapeutics treatment reduces HCV replication in the liver.

New index more precisely determines the probability of reducing liver fat during lifestyle interventions.

A recently-published Institute for Safe Medication Practices (ISMP) report details updated concerns about newer drugs used to treat hepatitis C virus (HCV).

The new test service helps physicians assess patient’s responses to antiretroviral therapy for HBV.

Simeprevir was approved by the FDA in late 2013 for hepatitis C virus.

Severe adverse events may be associated with new class of hepatitis C medications.

Sofosbuvir/velpatasvir/voxilaprevir granted accelerated assessment for the treatment of hepatitis C.

Regimen of sofosbuvir/velpatasvir/voxilaprevir treats hepatitis C virus genotypes 1 to 6.

Conflicts of interest among committee members who set hepatitis C treatment guidelines may influence decision-making.

Worldwide there are more than 350,000 HCV-related deaths per year.

Quest Diagnostics launches a test that determines patient response to costly hepatitis B virus drugs.

Patient with a failing liver who received an HCV-infected liver cured of the virus.

Cognitive impairment more prevalent in patients with HIV coinfection than in those with hepatitis C infection alone.

Successful treatment with buprenorphine is crucial for patients with opioid use disorder.

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Glecaprevir/pibrentasvir is indicated as an eight-week treatment for hepatitis C among patients without cirrhosis.

Company seeks to leverage technologies to address unmet needs.

Top news of the day from across the health care landscape.

This fixed-dose combination of sofosbuvir and velpatasvir is indicated to treat chronic HCV genotypes 1-6.

Novartis partners with Conatus to develop a new drug for non-alcoholic steatohepatitis.